Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bevacizumab for Recurrent Malignant Glioma
NCT00271609Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2005
- Primary completion
- Mar 2011
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of bevacizumab in glioblastoma (GBM), anaplastic glioma, sponsored by National Cancer Institute. Started Dec 2005; status: completed.
02
Drugs
bevacizumab
03
Conditions
glioblastoma (GBM)anaplastic glioma
Beyond the preview
Go deeper on NCT00271609.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00271609.